10-K: Schrodinger, Inc. Reports Full Year 2024 Results, Highlights Progress in Drug Discovery Programs

Schrodinger, Inc. reports its full year 2024 financial results, showcasing growth in software revenue and advancements in its collaborative and proprietary drug discovery programs.

Summary

• Schrodinger, Inc. released its 10-K filing for the fiscal year ended December 31, 2024.
• The company's software revenue increased by 13% to $180.4 million, driven by adoption in the biopharmaceutical industry.
• The company had a net loss of $187.1 million for the year.
• Schrodinger is progressing its proprietary drug discovery programs, including SGR-1505, SGR-2921 and SGR-3515, with initial data expected in 2025.
• The company has a research collaboration with Novartis, eligible for up to $2.272 billion in milestones.
• The company's customer retention rate for customers with an ACV of at least $100,000 was 95% for the year ended December 31, 2024.
• As of December 31, 2024, the company had cash, cash equivalents, restricted cash, and marketable securities of $367.5 million.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's positive growth in software revenue and progress in drug discovery programs, the significant net loss and competitive landscape temper the overall outlook.

Positives

• Software revenue experienced a 13% increase, indicating strong market adoption.
• High customer retention rate (95% for customers with ACV >= $100k) suggests customer satisfaction and value.
• Advancement of proprietary drug discovery programs into Phase 1 clinical trials demonstrates progress and potential for future revenue.
• The Novartis collaboration provides significant potential milestone payments and royalties.
• The company received $47.6 million from the equity stake in Morphic in connection with Morphic's acquisition by Lilly.
• The company launched an initiative to expand its computational platform to predict toxicology risk early in drug discovery, funded by $19.5 million in grants from the Bill & Melinda Gates Foundation.

Negatives

• The company reported a net loss of $187.1 million for the year ended December 31, 2024.
• Drug discovery revenue decreased by 53% compared to the previous year.
• The company is dependent on collaborators for the development and potential commercialization of product candidates.

Risks

• The company has a history of operating losses and expects to incur losses over the next several years.
• The company may require additional capital to fund its operations.
• The biopharmaceutical industry is highly competitive.
• Clinical trials are expensive and can take many years to complete, and their outcome is inherently uncertain.
• The company relies on third parties to conduct its clinical trials and manufacture its product candidates.
• The company's internal information technology systems, or those of its third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions.

Future Outlook

The company anticipates continued growth in software revenue, driven by broader adoption in the biopharmaceutical industry, and plans to progress its proprietary drug discovery programs.

Management Comments

• Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth.
• We evaluate our proprietary drug discovery programs individually to determine the advisability of entering into preclinical and clinical development ourselves to co-develop them with leading industry partners, entering into collaborations, or out-licensing programs to optimize their development and clinical and commercial potential.

Industry Context

The document highlights the competitive landscape in both the software and drug discovery sectors, noting the presence of major pharmaceutical companies, established biotechnology firms, and emerging AI-driven competitors. The company emphasizes its differentiated physics-based computational platform as a key competitive advantage.

Comparison to Industry Standards

• The document mentions competitors such as BIOVIA, Chemical Computing Group, Cresset Biomolecular Discovery, and others in the software space.
• In drug discovery, it acknowledges competition from AbbVie, Ono Pharmaceutical, HotSpot Therapeutics, and Recursion Pharmaceuticals for MALT1 inhibitors, and other companies developing CDC7 and Wee1 inhibitors.
• The document benchmarks SGR-3515 against Zentalis' ZN-c3 and Repare Therapeutics' RP-6306, highlighting an improved selectivity profile.

Related Party Transactions

• The Bill & Melinda Gates Foundation, an entity under common control with Bill & Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations.
• The Company paid consulting fees to a member of its board of directors.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and market conditions.
• Employees will be impacted by the company's ability to fund operations and invest in research and development.
• Customers will benefit from the company's continued investment in its computational platform and software solutions.
• Collaborators will be impacted by the company's ability to progress its drug discovery programs and secure partnerships.

Next Steps

• Report initial data from the Phase 1 clinical trial of SGR-1505 in the second quarter of 2025.
• Report initial data from the Phase 1 clinical trial of SGR-2921 in the second half of 2025.
• Report initial data from the Phase 1 clinical trial of SGR-3515 in the second half of 2025.
• Continue to work with collaborators on advancing collaborative programs through discovery research stages.
• Progress the development of proprietary drug discovery programs.

Key Dates

Keywords

Drug discovery, Software, Computational platform, Clinical trials, Revenue, Milestone payments, Biopharmaceutical, SGR-1505, SGR-2921, SGR-3515, Novartis, Collaboration